Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

被引:31
|
作者
Findlow, Jamie [1 ,2 ]
Bai, Xilian [1 ,2 ]
Findlow, Helen [1 ,2 ]
Newton, Emma [1 ,2 ]
Kaczmarski, Ed [1 ,2 ]
Miller, Elizabeth [3 ]
Borrow, Ray [1 ,2 ,4 ]
机构
[1] Publ Hlth England, Publ Hlth Lab, Manchester M13 9WZ, Lancs, England
[2] Manchester Royal Infirm, Manchester Med Microbiol Partnership, Manchester M13 9WZ, Lancs, England
[3] Publ Hlth England, Immunisat Dept, Hlth Protect Serv, London NW9 5EQ, England
[4] Univ Manchester, Inflammat Sci Res Grp, Sch Translat Med, Manchester M13 9PL, Lancs, England
关键词
Meningococcal; Vaccine; 4CMenB; ACWY-CRM; Laboratory workers; NEISSERIA-MENINGITIDIS SEROGROUP; IMMUNOLOGICAL HYPORESPONSIVENESS; POLYSACCHARIDE VACCINATION; GLYCOCONJUGATE VACCINE; UNITED-KINGDOM; HUMAN IMMUNITY; GROUP C; ANTIBODIES; ADULTS; STANDARDIZATION;
D O I
10.1016/j.vaccine.2015.05.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Safety precautions for laboratory staff working with meningococci should primarily rely on laboratory procedures preventing exposure to aerosols containing viable meningococci. Despite this, vaccination is a key component of protection in the occupational setting. In the UK in 2009, there were no licensed vaccines for meningococcal capsular group B or conjugate vaccines for capsular groups A, C, W and Y. We therefore undertook a Phase II trial in laboratory workers to investigate the safety and immunogenicity of a four component group B vaccine (4CMenB) and a quadrivalent group A, C,W and Y conjugate vaccine (ACWY-CRM). Enrolment was open to staff aged 18-65 years at the Public Health Laboratory, Manchester who may have had a potential occupational exposure risk to meningococci. 4CMenB was administered at 0,2 and 6 months in the non-dominant arm and ACWY-CRM concomitantly at 0 months in the dominant arm. Pre- and post-vaccination blood samples were taken and analysed by the serum bactericidal antibody (SBA) assay against A, C, W and Y strains and a panel of seven diverse group B strains. Diary cards were used to record any local and systemic reactions following each vaccination. In total, 38 staff were enrolled and received initial vaccinations with 31 completing the trial per protocol. Both vaccines were proven safe, with local reactogenicity being more commonly reported following 4CMenB than ACWY-CRM. High proportions of subjects had putative protective SBA titres pre-vaccination, with 61-84 and 61-87% protected against A, C, W and Y strains and diverse MenB strains, respectively. Post-vaccination, SBA titres increased with 95-100 and 90-100% of subjects with protective SBA titres against A, C, W and Y strains and diverse MenB strains, respectively. These data suggest that 4CMenB and ACWY-CRM are safe when administered concomitantly and have the potential to enhance protection for laboratory workers. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3322 / 3330
页数:9
相关论文
共 50 条
  • [21] Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
    Vesikari, Timo
    Esposito, Susanna
    Prymula, Roman
    Ypma, Ellen
    Kohl, Igor
    Toneatto, Daniela
    Dull, Peter
    Kimura, Alan
    LANCET, 2013, 381 (9869): : 825 - 835
  • [22] Immunogenicity and safety of conjugate meningococcal group C vaccine in infants.
    Rennels, MB
    Edwards, KM
    Keyseding, HL
    Reisinger, KS
    Hogerman, DA
    Kimura, A
    Malinoski, FJ
    PEDIATRIC RESEARCH, 1996, 39 (04) : 1083 - 1083
  • [24] Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study
    Bryan, Philip
    Seabroke, Suzie
    Wong, Jenny
    Donegan, Katherine
    Webb, Elizabeth
    Goldsmith, Charlotte
    Vipond, Caroline
    Feavers, Ian
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (06): : 395 - 403
  • [25] Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Kshirsagar, Nilima
    Mur, Naidu
    Thatte, Urmila
    Gogtay, Nithya
    Viviani, Simonetta
    Preziosi, Marie-Pierre
    Elie, Cheryl
    Findlow, Helen
    Carlone, George
    Borrow, Ray
    Parulekar, Varsha
    Plikaytis, Brian
    Kulkarni, Prasad
    Imbault, Nathalie
    LaForce, F. Marc
    VACCINE, 2007, 25 : A101 - A107
  • [26] Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants
    Klein, Nicola P.
    Reisinger, Keith S.
    Johnston, William
    Odrljin, Tatjana
    Gill, Christopher J.
    Bedell, Lisa
    Dull, Peter
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (01) : 64 - 71
  • [27] Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis
    Flacco, Maria Elena
    Manzoli, Lamberto
    Rosso, Annalisa
    Marzuillo, Carolina
    Bergamini, Mauro
    Stefanati, Armando
    Cultrera, Rosario
    Villari, Paolo
    Ricciardi, Walter
    Ioannidis, John P. A.
    Contopoulos-Ioannidis, Despina G.
    LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 461 - 472
  • [28] Aseptic meningitis associated with routine infant immunisation visits that include the group B meningococcal vaccine, 4CMenB
    Riordan, Andrew
    Ladhani, Shamez N.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 (12) : 1237 - +
  • [29] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    Miguel O’Ryan
    Jeffrey Stoddard
    Daniela Toneatto
    James Wassil
    Peter M. Dull
    Drugs, 2014, 74 : 15 - 30
  • [30] A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
    O'Ryan, Miguel
    Stoddard, Jeffrey
    Toneatto, Daniela
    Wassil, James
    Dull, Peter M.
    DRUGS, 2014, 74 (01) : 15 - 30